• Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Ala763_Tyr764insPheGlnGluAla (c.2284-5_2290dup); ClinVar=VCV000045248; Zygosity=Unspecified (PubMed=24353160).
  

PubMed=24353160; DOI=10.1126/scitranslmed.3007205; PMCID=PMC3954775
Yasuda H., Park E., Yun C.-H., Sng N.J., Lucena-Araujo A.R., Yeo W.-L., Huberman M.S., Cohen D.W., Nakayama S., Ishioka K., Yamaguchi N., Hanna M., Oxnard G.R., Lathan C.S., Moran T., Sequist L.V., Chaft J.E., Riely G.J., Arcila M.E., Soo R.A., Meyerson M.L., Eck M.J., Kobayashi S.S., Costa D.B.
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Sci. Transl. Med. 5:216ra177.1-216ra177.10(2013)

PubMed=31467113; DOI=10.1158/1541-7786.MCR-19-0419; PMCID=PMC6872223
Udagawa H., Hasako S., Ohashi A., Fujioka R., Hakozaki Y., Shibuya M., Abe N., Komori T., Haruma T., Terasaka M., Fujita R., Hashimoto A., Funabashi K., Yasuda H., Miyadera K., Goto K., Costa D.B., Kobayashi S.S.
TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically relevant EGFR mutations.
Mol. Cancer Res. 17:2233-2243(2019)